Showing results (261-270 of 679) with videos related to
Sort By:
Pageof 68
International Journal of Hematology|August 8, 2019
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. TrialsMeletios A Dimopoulos, Philippe Moreau, Shinsuke Iida, et al.Haematologica|October 18, 2006
Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II studyJean-Luc Harousseau, Michel Attal, Xavier Leleu, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2012
Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myelomaSagar Lonial, Ravi Vij, Jean-Luc Harousseau, et al.International Journal of Molecular Sciences|January 4, 2018
Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma CellsPierre-Samuel Gillardin, Géraldine Descamps, Sophie Maiga, et al.Leukemia|August 7, 2025
Simultaneous whole-body multi-parametric 2-[18F]FDG-PET/MRI in smoldering multiple myeloma assessment: diagnostic and prognostic impactBastien Jamet, Cyrille Touzeau, Hatem Necib, et al.Thrombosis Research|December 8, 2023
Venous thromboembolism prophylaxis and multiple myeloma patients in real-life: Results of a large survey and clinical guidance recommendations from the IFM groupLaurent Frenzel, Olivier Decaux, Margaret Macro, et al.International Journal of Radiation Oncology, Biology, Physics|September 29, 2022
Phase 1 Study of the Combination of Escalated Total Marrow Irradiation Using Helical Tomotherapy and Fixed High-Dose Melphalan (140 mg/m²) Followed by Autologous Stem Cell Transplantation at First Relapse in Multiple MyelomaAxel Cailleteau, Philippe Maingon, Sylvain Choquet, et al.European Journal of Nuclear Medicine and Molecular Imaging|October 2, 2020
Random survival forest to predict transplant-eligible newly diagnosed multiple myeloma outcome including FDG-PET radiomics: a combined analysis of two independent prospective European trialsBastien Jamet, Ludivine Morvan, Cristina Nanni, et al.Blood|September 3, 2017
Rituximab-based first-line treatment of cGVHD after allogeneic SCT: results of a phase 2 studyFlorent Malard, Myriam Labopin, Ibrahim Yakoub-Agha, et al.Annals of Hematology|November 21, 2014
Initial fluconazole prophylaxis may not be required in adults with acute leukemia or myelodysplastic/myeloproliferative disorders after reduced intensity conditioning peripheral blood stem cell allogeneic transplantationEolia Brissot, Xavier Cahu, Thierry Guillaume, et al.Pageof 68